Testosterone Enanthate vs AndroGel: How to Switch Between Them Safely

Why Patients Switch Formulations

Most men on TRT don't switch because their medication failed. They switch because their life circumstances changed or because side-effect tolerability shifted over time. Understanding why a switch is requested helps the prescriber pick the right transition plan.

Lifestyle and Preference Drivers

Injection-based testosterone enanthate appeals to men who want stable trough-to-peak cycling and less daily burden. A single intramuscular injection every 7 to 14 days replaces 7 to 14 consecutive gel applications. But some men develop injection-site discomfort, oil-based nodules, or simple needle fatigue after months or years on intramuscular therapy. The Endocrine Society's 2018 clinical practice guideline acknowledges that "patient preference, pharmacokinetics, treatment burden, and cost" should all factor into formulation selection [2].

Clinical Drivers

Gel formulations carry a risk of secondary transfer to household contacts (partners, children) through skin contact. The FDA's boxed warning on AndroGel specifically addresses virilization in children exposed to residual gel on the patient's skin [3]. Men with young children at home sometimes switch to injections to eliminate that risk entirely. Conversely, men with polycythemia (hematocrit above 54%) on injections may benefit from switching to transdermal gel, which produces lower peak testosterone levels and a smaller erythropoietic stimulus according to data published in the Journal of Clinical Endocrinology & Metabolism [4].

Pharmacokinetic Differences That Matter for Switching

The reason switching requires careful timing (and is not as simple as stopping one and starting the other on the same day) comes down to how each formulation releases testosterone into the bloodstream.

Testosterone Enanthate: Depot Release

Testosterone enanthate dissolved in sesame or cottonseed oil forms a depot in muscle tissue after injection. Serum testosterone peaks at roughly 48 to 72 hours post-injection, then declines over 7 to 14 days. The terminal half-life is approximately 4.5 days [5]. A man injecting 200 mg every 14 days will have a peak near 1,000 to 1,200 ng/dL and a trough that may dip below 400 ng/dL. That trough window is when gel therapy should begin.

AndroGel: Steady-State Absorption

AndroGel 1% delivers testosterone transdermally. About 10% of the applied dose is absorbed through the skin. Steady-state serum levels are reached within 24 to 48 hours of daily application, with minimal peak-to-trough fluctuation across the day [6]. Once application stops, serum testosterone falls to hypogonadal levels within 48 to 72 hours because there is no depot reservoir.

Why the Timing Gap Exists

If a patient applies gel too early after an injection, the residual depot plus the gel dose could push total testosterone well above 1,100 ng/dL, raising hematocrit and cardiovascular risk unnecessarily. If a patient injects too late after stopping gel, he may spend several days in a hypogonadal trough (below 300 ng/dL), experiencing fatigue, mood changes, and loss of libido. The clinical goal is to overlap the tail of the old formulation with the onset of the new one, without stacking supraphysiologic exposure.

Step-by-Step: Switching from Enanthate to AndroGel

This protocol applies to men on stable enanthate doses (100 to 200 mg every 7 to 14 days) who have documented steady-state labs within the prior 90 days.

Timing the Transition

Administer the final enanthate injection on the patient's usual schedule. Wait 7 days (one half-life beyond the typical peak clearance), then begin daily AndroGel application. For men on a 7-day injection cycle, the gel starts on the day the next injection would have been due. For men on a 14-day cycle, starting gel at day 7 rather than day 14 avoids a prolonged hypogonadal trough.

Dose Conversion

There is no published validated cross-formulation conversion factor. A practical starting point used in clinical practice:

| Prior Enanthate Dose | Starting AndroGel 1% Dose | |---|---| | 100 mg every 14 days | 50 mg/day (5 g gel) | | 100 mg every 7 days | 50 to 75 mg/day (5 to 7.5 g gel) | | 200 mg every 14 days | 50 to 75 mg/day (5 to 7.5 g gel) | | 200 mg every 7 days | 75 to 100 mg/day (7.5 to 10 g gel) |

These are empiric starting doses. The prescriber should recheck serum total testosterone drawn 2 to 4 hours after gel application at 4 to 6 weeks and titrate accordingly [2].

What the Patient Should Expect

Energy and libido may dip during days 5 through 10 of the transition as the depot clears and gel steady-state builds. This is normal. Patients should not double-apply gel or use leftover injectable testosterone to "bridge" the gap without clinician guidance.

Step-by-Step: Switching from AndroGel to Enanthate

Switching from a daily topical to an injectable depot is generally simpler because there is no long-acting reservoir to overlap with.

Timing the Transition

Apply the final dose of AndroGel on the patient's usual morning schedule. The next morning, administer the first testosterone enanthate injection. Because gel-derived testosterone clears within 48 to 72 hours and the injection peak does not arrive for another 48 to 72 hours, there is a brief overlap window that keeps serum levels in range without supraphysiologic stacking.

Dose Selection

Start at the dose that matches the patient's clinical target, not a "converted" dose from gel. Most men begin at 100 mg every 7 days or 200 mg every 14 days. The Endocrine Society guideline recommends targeting a mid-normal total testosterone of 400 to 700 ng/dL measured at trough (the morning of the next scheduled injection) [2].

Monitoring After the Switch

Draw labs at 4 to 6 weeks: total testosterone (trough), free testosterone, hematocrit, hemoglobin, and PSA. Hematocrit tends to rise more on injectable testosterone than on gel. A hematocrit above 54% requires dose reduction, increased injection frequency (to lower peaks), or therapeutic phlebotomy [7].

Head-to-Head Evidence: What We Know and Don't Know

No randomized controlled trial has directly compared testosterone enanthate injections to AndroGel in a switching approach. The strongest shared evidence base comes from the Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016.

The T-Trials

The T-Trials enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL across seven coordinated sub-studies [1]. The intervention arm used AndroGel 1% (dose-adjusted to target 500 to 800 ng/dL). Over 12 months, treated men showed improvements in sexual function (DISF-M-II score increase of 0.58 vs. Placebo, P<0.001), physical function (6-minute walk distance increased by 6.1 meters more than placebo), and vitality (FACIT-Fatigue score improvement of 2.41 points vs. Placebo). While the trial used gel specifically, the physiologic effects are attributable to testosterone itself, not to the delivery vehicle.

Injectable Data from Registry Studies

The European Male Ageing Study and registry data from Baylor College of Medicine have shown that intramuscular testosterone enanthate and cypionate produce equivalent improvements in lean mass, bone density, and sexual function compared to topical formulations when serum testosterone is matched [8]. The difference lies in pharmacokinetic profile, not in endpoint efficacy.

Practical Equivalence

"The choice between injectable and transdermal testosterone should be individualized. Both achieve therapeutic serum levels and comparable clinical outcomes when dosed correctly," states the Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism [2]. This sentence is the closest the field has to an official equivalence statement.

Situations Where One Formulation Is Clinically Preferred

While both formulations work, certain clinical scenarios tilt the decision.

Favor Gel Over Injection

Polycythemia management is the primary clinical reason. Gel produces lower peak testosterone levels and a flatter pharmacokinetic curve. A 2017 analysis in JCEM found that men on transdermal testosterone had a 40% lower rate of hematocrit exceeding 54% compared to men on intramuscular injections over 3 years [4]. Men with needle phobia, bleeding disorders, or who are on anticoagulant therapy may also be better served by gel.

Favor Injection Over Gel

Men with skin conditions (psoriasis, eczema, extensive scarring) at application sites may have erratic gel absorption. Men with young children or pregnant partners should avoid gel to prevent secondary transfer. Cost is another factor. Generic testosterone enanthate costs approximately $30 to $50 per month without insurance, while brand-name AndroGel 1% can exceed $500 per month, though generic testosterone gel 1% is available at roughly $80 to $150 per month [9].

"We commonly switch patients from gel to injections purely for cost reasons. The clinical outcome, when serum levels are matched, is the same," noted a pharmacokinetic review published in Translational Andrology and Urology [10].

Monitoring Protocol After Any Formulation Switch

A formulation change resets the monitoring clock. Treat the patient as if starting TRT for the first time for the purposes of lab surveillance.

Lab Panel at 4 to 6 Weeks Post-Switch

| Test | Target | Action if Out of Range | |---|---|---| | Total testosterone | 400 to 700 ng/dL (trough for injections, 2 to 4 hr post-application for gel) | Adjust dose up or down by 25% | | Free testosterone | Age-adjusted normal | Evaluate SHBG if discordant with total T | | Hematocrit | <54% | Dose reduction, phlebotomy, or consider switching to gel | | PSA | <4.0 ng/mL or <1.4 ng/mL rise over 12 months | Urology referral | | Estradiol | 20 to 50 pg/mL | Consider aromatase inhibitor if symptomatic |

Follow-Up Schedule

Repeat labs at 3 months post-switch, then every 6 to 12 months once stable, per the Endocrine Society and American Urological Association guidelines [2][11]. Bone mineral density testing (DEXA) should occur at baseline and at 1 to 2 years if osteoporosis was part of the original indication.

Common Mistakes During the Switch

Clinicians and patients make a few recurring errors during formulation transitions. Knowing them in advance prevents most problems.

Overlapping Full Doses

Applying gel while a full depot injection is still active (within the first 3 to 4 days post-injection) can push testosterone above 1,500 ng/dL transiently, raising hematocrit and potentially triggering acne flares or mood instability.

Skipping the Lab Recheck

Assuming the old dose "translates" to the new formulation without confirming it with bloodwork leads to under- or over-dosing that may persist for months. Bioavailability differs substantially: only about 10% of applied gel is absorbed, while 100% of injected enanthate enters the systemic circulation (gradually).

Stopping Ancillary Medications

Men taking anastrozole or hCG alongside TRT should not discontinue these during a formulation switch without explicit clinician instruction. Estradiol management and fertility preservation needs remain the same regardless of testosterone delivery vehicle.

Insurance and Prior Authorization Considerations

Switching formulations may trigger a new prior authorization requirement, even if the patient was previously approved for TRT. Most commercial insurers classify injectable testosterone enanthate as a generic preferred drug (Tier 1), while AndroGel sits on Tier 3 or requires step therapy documentation showing injection intolerance [12]. When switching from injection to gel, document the clinical rationale (polycythemia, needle phobia, transfer risk elimination is not applicable here since gel has the transfer risk) in the chart to support the prior authorization.

Patients moving from gel to injection rarely face prior authorization barriers since the injectable is the lower-cost option. Medicare Part D covers both, though copays vary by plan.